Surgical Science Sweden AB · OMXSTO:SUS
Surgical Science Sweden AB — Surgical Science — Q3 2026 Earnings Presentation
13 slides from Surgical Science Sweden AB's earnings presentation, Nov 12, 2026
Slide 1: Presentation of Interim Report Q3
Presentation of Interim Report Q3 ©2026 Surgical Science. | All rights reserved.
Slide 2: CEO comments – Q3 2026
CEO comments – Q3 2026 Revenue Adjusted EBIT ▪ Increasing profitability and important strategic progress SEK 260.2m SEK 37.8m ▫ Adjusted EBIT +15% – 15% margin, in line with financial target -1% reported | -1% fx-adj 15% margin | 17% fx-adj ▫ Gross margin 68% (65) and strong operating cash flow ▪ Ed
Slide 3: Ultrasound +14% – Aeris launched for emergency POCUS
Ultrasound +14% – Aeris launched for emergency POCUS
Slide 4: CEO comments – Q3 2026
CEO comments – Q3 2026 Revenue Adjusted EBIT ▪ Increasing profitability and important strategic progress SEK 260.2m SEK 37.8m ▫ Adjusted EBIT +15% – 15% margin, in line with financial target -1% reported | -1% fx-adj 15% margin | 17% fx-adj ▫ Gross margin 68% (65) and strong operating cash flow ▪ Ed
Slide 5: Q3: Increasing profitability and important strategic progress
Q3: Increasing profitability and important strategic progress SEKm 250 Q3: ▪ Net sales down 1% to SEKm 260.2 (263.6). In local currencies down 1%. 200 47% 52% 46% 50% 48% 45% 51% 45% ▪ Educational Products up 1%, 2% excl. FX. Regions: EMEA - 31%, APAC - 6%, Americas +30%. 47% 150 ▪ Industry down 4%,
Slide 6: Revenue streams
Revenue streams SEKm 8% 2% 4% 8% 6% 250 6% Q3: 4% 6% 11% ▪ License revenues: 29 % (25) of total revenues. 30% 25% 29% Assessment that total revenue loss due to 200 33% 34% 33% 28% 29% cancelled MoU will be less than the interval 8% 28% 9% previously stated ( SEKm 60 - 90). 150 10% 10% 9% 9% 10% 9% ▪
Slide 7: Costs and EBIT margin
Costs and EBIT margin Q3: ▪ Gross margin 68% (65). Higher license revenue and increased direct sales within Edu had a positive effect. ▪ Sales: 21% (21) of sales. SEKm 2.7 attributable to commissions Costs/margin as a percentage of sales* to distributors. Cost of goods sold 32% (3 5) ▪ Admin: 8% (8)
Slide 8: Organization
Organization No of employees at end of period: 324 (328) Men 228 ( 238 ) Women 96 (90) Israel 158 (152) Sweden 76 ( 70 ) USA 40 (54 ) UK 28 (33) Other 22 (19) * Offices / Development sites * Other : Primarily Germany and China. 5
Slide 9: Adjusted EBIT
Adjusted EBIT* SEKm 50% 250 Q3: 40% 200 ▪ Adjusted EBIT SEKm 37.8 (32.8), 15% (12). 150 30% ▪ FX - adjusted adjusted EBIT 100 20% SEKm 44.5, 17%. 10% YTD: 50 ▪ Adjusted EBIT SEKm 104.3 0 0% Q3 Q4 Q1 Q2 Q3 Q4 Q1 Q2 Q3 (46.1), 14% (6). 2024 2025 2026 -50 -10% ▪ FX - adjusted adjusted EBIT SEKm 134.8,
Slide 10: Finance net and taxes
Finance net and taxes Q3: ▪ Finance net SEKm 2.8 (2.9). Interest on bank balances, revaluation of internal loans and IFRS 16 effect. ▪ Tax expense SEKm 0.7 (9.7). Lower due to final tax return in the Israeli entity, which resulted in a positive adjustment. ▪ Net result SEKm 34.1 (20.4). YTD: ▪ Finan
Slide 11: Cash flow
Q3: Cash flow ▪ Cash flow from operating activities SEKm 42.5 (- 4.4). Change in working capital SEKm - 7.3 SEKm (- 44.6). Inventory and A/R increased. Prepaid 800 18% expenses and current liabilities have decreased. 700 16% 14% ▪ Cash flow from investing activities SEKm - 14.9 600 (- 10.9) mainly i
Slide 12: Questions?
Questions? ©2026 Surgical Science. | All rights reserved.
Slide 13: Thank you
Thank you Find out more at: www.surgicalscience.com ©2026 Surgical Science. | All rights reserved.